IIT2021-01-Shiao-CSF1Ri: Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
Latest Information Update: 26 Feb 2025
At a glance
- Drugs Axatilimab (Primary) ; Pembrolizumab (Primary)
- Indications Breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 21 Feb 2025 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
- 21 Feb 2025 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2026.
- 21 Feb 2025 Status changed from recruiting to active, no longer recruiting.